Furthermore, SGLT2 inhibitors have been shown to reduce hyperphosphorylated tau and Aβ accumulation while enhancing brain insulin signaling in a type 2 diabetes–AD mouse model (Sim et al. 2023). This evidence concerns the gene MAPT and Alzheimer disease.